Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

被引：4
|
作者：
Kelley, Robin Kate
Rimassa, Lorenza
Ryoo, Baek-Yeol
Park, Joong-Won
Blanc, Jean-Frederic
Chan, Stephen Lam
Dadduzio, Vincenzo
Yau, Thomas Cheung
Sen, Suvajit
Markby, David W.
Kaldate, Rajesh
El-Khoueiry, Anthony B.
Cheng, Ann-Lii
Meyer, Tim
Abou-Alfa, Ghassan K.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Humanitas Clin & Res Ctr, Rozzano, Italy
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Natl Canc Ctr Korea, Goyang Si, South Korea
[5] Grp Hosp St Andre, Serv Hepato Gastroenterol & Oncol Digest, Bordeaux, France
[6] Chinese Univ Hong Kong, State Key Lab Oncol South China, Dept Clin Oncol, Hong Kong, Peoples R China
[7] IRCCS, Ist Oncol Veneto, Padua, Italy
[8] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[9] Exelixis Inc, Alameda, CA USA
[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[11] Natl Taiwan Univ Hosp, Taipei, Taiwan
[12] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[13] UCL, Canc Inst, London, England
[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.423
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
423
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Longitudinal analysis of the quality of life (QoL) within a randomized phase III trial: Octreotide versus placebo for the patients having advanced hepatocellular carcinoma (HCC)
    Dumas, F.
    Barbare, J.
    Aparicio, T.
    Bouche, O.
    Lombard-Bohas, C.
    Faroux, R.
    Seitz, J.
    Raoul, J.
    Bedenne, L.
    Bonnetain, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth
    Gruellich, Carsten
    Nott, Louise M.
    Cuff, Katharine
    Gil, Thierry
    Jensen, Niels Viggo
    Chevreau, Christine
    Negrier, Sylvie
    Depenbusch, Reinhard
    Bergmann, Lothar
    Cornelio, Izzy
    Champsaur, Anne
    Escudier, Bernard
    Pal, Sumanta
    Powles, Thomas
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 1 - 10
  • [43] Matching-Adjusted Indirect Comparison of Cabozantinib (C) Versus Regorafenib (R) in Advanced Hepatocellular Carcinoma (HCC)
    Venerito, Morino
    Kelley, R. K.
    Mollon, P.
    Blanc, J. F.
    Daniele, B.
    Yau, T.
    Cheng, A. L.
    Valcheva, V.
    Azocar, A. Remiro
    Baio, G.
    Li, Y.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 60 - 60
  • [44] Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial
    Dollinger, Matthias M.
    Lautenschlaeger, Christine
    Lesske, Joachim
    Tannapfel, Andrea
    Wagner, Anna-Dorothea
    Schoppmeyer, Konrad
    Nehls, Oliver
    Welker, Martin-Walter
    Wiest, Reiner
    Fleig, Wolfgang E.
    BMC CANCER, 2010, 10
  • [45] SPONTANEOUS HEPATOCELLULAR CARCINOMA (HCC) AND SERUM ALPHA-FETOPROTEIN (AFP) QUANTITATION IN C3H-A FB MICE
    PRINCLER, GL
    VLAHAKIS, G
    MCINTIRE, KR
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 209 - 209
  • [46] Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial
    Matthias M Dollinger
    Christine Lautenschlaeger
    Joachim Lesske
    Andrea Tannapfel
    Anna-Dorothea Wagner
    Konrad Schoppmeyer
    Oliver Nehls
    Martin-Walter Welker
    Reiner Wiest
    Wolfgang E Fleig
    BMC Cancer, 10
  • [47] Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
    Zhu, A. X.
    Galle, P. R.
    Llovet, J. M.
    Finn, R. S.
    Kang, Y-K.
    Yen, C. J.
    Assenat, E.
    Brandi, G.
    Motomura, K.
    Ohno, I.
    Daniele, B.
    Vogel, A.
    Yamashita, T.
    Hsu, C-H.
    Meyer, T.
    Widau, R.
    Schelman, W.
    Wang, C.
    Hsu, Y.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Ma, Yuk Ting
    Peck-Radosavljevic, Markus
    Ross, Paul J.
    Graham, Janet Shirley
    Fartoux, Laetitia
    Deptala, Andrzej
    Wenz, Arne
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [49] Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
    Kelley, Robin Kate
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Bolondi, Luigi
    Chan, Stephen L.
    Lim, Ho Yeong
    Baron, Ari D.
    Parnis, Francis
    Knox, Jennifer
    Cattan, Stephane
    Yau, Thomas
    Lougheed, Julie C.
    Milwee, Steven
    El-Khoueiry, Anthony B.
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    ESMO OPEN, 2020, 5 (04) : 1 - 9
  • [50] Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2
    Galle, Peter R.
    Kudo, Masatoshi
    Llovet, Josep M.
    Finn, Richard S.
    Karwal, Mark
    Pezet, Denis
    Kim, Tae-You
    Yang, Tsai-Sheng
    Zagonel, Vittorina
    Tomasek, Jiri
    Phelip, Jean Marc
    Touchefeu, Yann
    Koh, Su-Jin
    Stirnimann, Guido
    Wang, Chunxiao
    Ogburn, Kenyon
    Abada, Paolo
    Widau, Ryan C.
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345